Despite the presence of identical catalytic sites and the high sequence conservation (95%) of the M1-spliced isoform, selective targeting of human PK-M2 that included only the region involved in allosteric regulation was shown to offer a chance of targeting cellular metabolism for the treatment of malignant tumours [40, 42]. Here, PKM is linked to cancer.